These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12558462)

  • 21. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD; Sandoz MS; Keusch GW
    Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
    Seng WK; Hwang SJ; Han DC; Teong CC; Chan J; Burke TA; Carides GW; Choi YJ
    Nephrology (Carlton); 2005 Oct; 10(5):520-4. PubMed ID: 16221106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
    Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
    Brenner BM; Cooper ME; de Zeeuw D; Grunfeld JP; Keane WF; Kurokawa K; McGill JB; Mitch WE; Parving HH; Remuzzi G; Ribeiro AB; Schluchter MD; Snavely D; Zhang Z; Simpson R; Ramjit D; Shahinfar S;
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):328-35. PubMed ID: 11967819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF; Curran MP; Goa KL; Perry CM
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
    J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
    de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
    Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The RENAAL Study. Effect of losartan on diabetic nephropathy].
    Kuhlmann MK; Köhler H
    Internist (Berl); 2002 May; 43(5):675-7. PubMed ID: 12085539
    [No Abstract]   [Full Text] [Related]  

  • 38. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
    Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
    Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
    Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.